Ximelagatran as a New Oral Anticoagulant for Thrombosis

REFERENCES

• 1 Budnitz D S, Pollock D A, Mendelsohn A B, Weidenbach K N, McDonald A K, Annest J L. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system.  Ann Emerg Med. 2005;  45 197-206
• 2 Pirmohamed M, James S, Meakin S et al.. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.  BMJ. 2004;  329 15-19
• 3 Runciman W B, Roughead E E, Semple S J, Adams R J. Adverse drug events and medication errors in Australia.  Int J Qual Health Care. 2003;  15(Suppl 1) i49-i59
• 4 Horton J D, Bushwick B M. Warfarin therapy: evolving strategies in anticoagulation.  Am Fam Physician. 1999;  59 635-646
• 5 Olsson S B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.  Lancet. 2003;  362 1691-1698
• 6 Albers G W, Diener H C, Frison L et al.. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.  JAMA. 2005;  293 690-698
• 7 Lee W M, Larrey D, Olsson R et al.. Hepatic findings in long-term clinical trials of ximelagatran.  Drug Saf. 2005;  28 351-370
• 8 Christiansen H M, Lassen M R, Borris L C et al.. Biologic tolerance of two different low molecular weight heparins.  Semin Thromb Hemost. 1991;  17 450-454
• 9 Christiansen H M, Lassen M R, Borris L C et al.. Biological tolerance of logiparin, a low molecular weight heparin used in patients undergoing total hip replacement.  Semin Thromb Hemost. 1991;  17(Suppl 2) 224-227
• 10 Eriksson B I, Bergqvist D, Kälebo P et al.. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.  Lancet. 2002;  360 1441-1447
• 11 Dahl O E, Pedersen T, Kierulf P et al.. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery.  Thromb Res. 1993;  70 451-458
• 12 Dahl O E, Aspelin T, Arnesen H et al.. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery.  Thromb Res. 1995;  80 299-306
• 13 Dahl O E, Andreassen G, Aspelin T et al.. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin).  Thromb Haemost. 1997;  77 26-31
• 14 Gallino A, Haeberli A, Hess T, Mombelli G, Straub P W. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin.  Am Heart J. 1986;  112 285-290
• 15 Granger C B, Miller J M, Bovill E G et al.. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes.  Circulation. 1995;  91 1929-1935
• 16 Genewein U, Haeberli A, Straub P W, Beer J H. Rebound after cessation of oral anticoagulant therapy: the biochemical evidence.  Br J Haematol. 1996;  92 479-485
• 17 Andersen K, Dellborg M, Emanuelsson H, Grip L, Swedberg K. Thrombin inhibition with inogatran for unstable angina pectoris: evidence for reactivated ischaemia after cessation of short-term treatment.  Coron Artery Dis. 1996;  7 673-681
• 18 Gold H K, Torres F W, Garabedian H D et al.. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.  J Am Coll Cardiol. 1993;  21 1039-1047
• 19 Wallentin L, Wilcox R G, Weaver W D et al.. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.  Lancet. 2003;  362 789-797